Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

Phase 2AC-201Positive

AI Analysis

Summary

Accro Bioscience announced IND clearance from China's NMPA for a Phase II/III clinical trial of AC-201, a selective TYK2/JAK1 inhibitor for non-segmental vitiligo treatment, with development support from Shanghai Fosun Pharmaceutical.

Clinical Trial Data

Phase

II/III

Outcome Details

IND clearance from NMPA for Phase II/III clinical trial

Importance:6/10

Sentiment:

0.70

IND clearanceNMPA approvalTYK2/JAK1 inhibitorvitiligoChinaclinical development

Related Companies

$BHIC $INTI $CHHE

Read the original article

Published by PR Newswire Biotech on September 8, 2026 12:20 PM

Read Original